Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Kaufman

Interventional Pain Medicine Wells, ME Doctor of Osteopathy

NPI 1619996063 CMS profile 163709

952 Post Rd, Unit 8, Wells, ME 04090

Open in the dashboard

General payments

$2,004

68 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Kaufman of Wells, ME is reported in the CMS Open Payments database as having received $2,004 across 68 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75 3
2024 General $652 7
2023 General $278 13
2022 General $99 2
2021 General $81 2
2020 General $173 11
2019 General $645 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Kaufman
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Brian Kaufman were reported at $75. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Brian Kaufman Interventional Pain Medicine median Middle half National median
2019 $645 $684 $216–$2,079 $163
2020 $173 $382 $122–$1,109 $114
2021 $81 $552 $167–$1,554 $132
2022 $99 $605 $187–$1,924 $149
2023 $278 $671 $195–$1,915 $160
2024 $652 $684 $206–$1,837 $164
2025 $75 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $705 7 payments
  2. AbbVie, Inc. $214 12 payments
  3. Teva Pharmaceuticals USA, Inc. $191 6 payments
  4. Scilex Pharmaceuticals Inc. $124 7 payments
  5. Pfizer Inc. $105 7 payments
  6. GRT US Holding, Inc. $90 2 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $86 3 payments
  8. Daiichi Sankyo Inc. $85 5 payments
  9. Averitas Pharma Inc. $82 3 payments
  10. Lilly USA, LLC $74 4 payments
  11. Other $248 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,533 66 payments
  2. Travel and Lodging $471 2 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $677 6 payments
  2. Qutenza $172 5 payments
  3. Ajovy $146 3 payments
  4. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $92 5 payments
  5. QULIPTA $89 5 payments
  6. RELISTOR $86 3 payments
  7. Morphabond ER $85 5 payments
  8. LYRICA $84 6 payments
  9. EMGALITY $74 4 payments
  10. XTAMPZA $73 2 payments
  11. Other $792 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$137,271

Of which drugs: $7,272

Medicare patients

339

Average age 72

Services billed

24,273

205 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Depression 33%
Diabetes 31%
Chronic kidney disease 23%
Ischemic heart disease 22%
COPD 22%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 193 19,541 $1,989
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 13 25 $1,416
Injection, methylprednisolone acetate, 40 mg J1030 Office 78 164 $763
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 140 2,201 $181

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record